Home > > > > > Report Detail

Chronic Respiratory Disease Drug Development Pipeline Review, 2018

Publisher Name :
Date: 30-Nov-2018
No. of pages: 361

Summary

This report provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, being overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. There are 275 products in development for this indication.

COPD is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs, leading to shortness of breath and blocked airflow to the lungs. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over time, increasing complications. The main risk factor is smoking. Exposure to chemicals and air pollution also contribute in the development of COPD. There are 187 products in development for this indication.

IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. There are 136 products in development for this indication.

Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.

Scope


  • Which companies are the most active within each pipeline?

  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened in this disease area?


Reasons to buy


  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Chronic Respiratory Disease Drug Development Pipeline Review, 2018

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 11

2 Introduction 12
2.1 Chronic Respiratory Disease Report Coverage 12
2.2 Asthma - Overview 12
2.3 Chronic Obstructive Pulmonary Disease (COPD) - Overview 12
2.4 Idiopathic Pulmonary Fibrosis - Overview 12

3 Therapeutics Development 13
3.1 Asthma 13
3.2 Chronic Obstructive Pulmonary Disease (COPD) 33
3.3 Idiopathic Pulmonary Fibrosis 51

4 Therapeutics Assessment 65
4.1 Asthma 65
4.2 Chronic Obstructive Pulmonary Disease (COPD) 81
4.3 Idiopathic Pulmonary Fibrosis 94

5 Companies Involved in Therapeutics Development 106
5.1 Asthma 106
5.2 Chronic Obstructive Pulmonary Disease (COPD) 172
5.3 Idiopathic Pulmonary Fibrosis 223

6 Dormant Projects 259
6.1 Asthma 259
6.2 Chronic Obstructive Pulmonary Disease (COPD) 279
6.3 Idiopathic Pulmonary Fibrosis 302

7 Discontinued Products 307
7.1 Asthma 307
7.2 Chronic Obstructive Pulmonary Disease (COPD) 311
7.3 Idiopathic Pulmonary Fibrosis 316

8 Product Development Milestones 317
8.1 Asthma 317
8.2 Chronic Obstructive Pulmonary Disease (COPD) 331
8.3 Idiopathic Pulmonary Fibrosis 345

9 Appendix 360
9.1 Methodology 360
9.2 Coverage 360
9.3 Secondary Research 360
9.4 Primary Research 360
9.5 Expert Panel Validation 360
9.6 Contact Us 360
9.7 Disclaimer 361

List of Tables

Table 1: Number of Products under Development for Asthma 13
Table 2: Number of Products under Development by Companies, Asthma 15
Table 3: Number of Products under Development by Universities/Institutes, Asthma 20
Table 4: Products under Development by Companies, Asthma 21
Table 5: Products under Development by Universities/Institutes, Asthma 31
Table 6: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) 33
Table 7: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 34
Table 8: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 38
Table 9: Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 39
Table 10: Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 50
Table 11: Number of Products under Development for Idiopathic Pulmonary Fibrosis 51
Table 12: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis 53
Table 13: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 56
Table 14: Products under Development by Companies, Idiopathic Pulmonary Fibrosis 57
Table 15: Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 64
Table 16: Number of Products by Stage and Target, Asthma 66
Table 17: Number of Products by Stage and Mechanism of Action, Asthma 72
Table 18: Number of Products by Stage and Route of Administration, Asthma 78
Table 19: Number of Products by Stage and Molecule Type, Asthma 80
Table 20: Number of Products by Stage and Target, Chronic Obstructive Pulmonary Disease (COPD) 82
Table 21: Number of Products by Stage and Mechanism of Action, Chronic Obstructive Pulmonary Disease (COPD) 87
Table 22: Number of Products by Stage and Route of Administration, Chronic Obstructive Pulmonary Disease (COPD) 92
Table 23: Number of Products by Stage and Molecule Type, Chronic Obstructive Pulmonary Disease (COPD) 93
Table 24: Number of Products by Stage and Target, Idiopathic Pulmonary Fibrosis 95
Table 25: Number of Products by Stage and Mechanism of Action, Idiopathic Pulmonary Fibrosis 99
Table 26: Number of Products by Stage and Route of Administration, Idiopathic Pulmonary Fibrosis 103
Table 27: Number of Products by Stage and Molecule Type, Idiopathic Pulmonary Fibrosis 105
Table 28: Asthma - Pipeline by 4D Pharma PLC 106
Table 29: Asthma - Pipeline by AB Science SA 106
Table 30: Asthma - Pipeline by AbbVie Inc 107
Table 31: Asthma - Pipeline by Abeome Corp 107
Table 32: Asthma - Pipeline by Accolade Pharmaceuticals LLC 108
Table 33: Asthma - Pipeline by Adamis Pharmaceuticals Corp 108
Table 34: Asthma - Pipeline by ALK-Abello AS 109
Table 35: Asthma - Pipeline by Allergan Plc 110
Table 36: Asthma - Pipeline by Allergopharma GmbH & Co KG 111
Table 37: Asthma - Pipeline by Almirall SA 111
Table 38: Asthma - Pipeline by Amgen Inc 112
Table 39: Asthma - Pipeline by Amphastar Pharmaceuticals Inc 112
Table 40: Asthma - Pipeline by AnaptysBio Inc 113
Table 41: Asthma - Pipeline by AnGes Inc 113
Table 42: Asthma - Pipeline by Antisense Therapeutics Ltd 114
Table 43: Asthma - Pipeline by Apollo Endosurgery Inc 114
Table 44: Asthma - Pipeline by ASIT Biotech SA 115
Table 45: Asthma - Pipeline by Aslan Pharmaceuticals Pte Ltd 115
Table 46: Asthma - Pipeline by Astellas Pharma Inc 116
Table 47: Asthma - Pipeline by AstraZeneca Plc 117
Table 48: Asthma - Pipeline by Aurigene Discovery Technologies Ltd 117
Table 49: Asthma - Pipeline by Biocon Ltd 118
Table 50: Asthma - Pipeline by BiosanaPharma BV 118
Table 51: Asthma - Pipeline by Biotec Pharmacon ASA 119
Table 52: Asthma - Pipeline by Boehringer Ingelheim GmbH 119
Table 53: Asthma - Pipeline by Celon Pharma SA 120
Table 54: Asthma - Pipeline by Chiesi Farmaceutici SpA 121
Table 55: Asthma - Pipeline by Crossject SA 121
Table 56: Asthma - Pipeline by CrystalGenomics Inc 122
Table 57: Asthma - Pipeline by CSL Ltd 123
Table 58: Asthma - Pipeline by CSPC Pharmaceutical Group Limited 123
Table 59: Asthma - Pipeline by Cumberland Pharmaceuticals Inc 124
Table 60: Asthma - Pipeline by Cynata Therapeutics Ltd 124

List of Figures

Figure 1: Number of Products under Development for Asthma 13
Figure 2: Number of Products under Development by Companies, Asthma 14
Figure 3: Number of Products under Development by Universities/Institutes, Asthma 19
Figure 4: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD 33
Figure 5: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 34
Figure 6: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 38
Figure 7: Number of Products under Development for Idiopathic Pulmonary Fibrosis 51
Figure 8: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis 52
Figure 9: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 56
Figure 10: Number of Products by Top 10 Targets, Asthma 65
Figure 11: Number of Products by Stage and Top 10 Targets, Asthma 65
Figure 12: Number of Products by Top 10 Mechanism of Actions, Asthma 71
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Asthma 71
Figure 14: Number of Products by Top 10 Routes of Administration, Asthma 76
Figure 15: Number of Products by Stage and Top 10 Routes of Administration, Asthma 77
Figure 16: Number of Products by Top 10 Molecule Types, Asthma 78
Figure 17: Number of Products by Stage and Top 10 Molecule Types, Asthma 79
Figure 18: Number of Products by Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD) 81
Figure 19: Number of Products by Stage and Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD) 81
Figure 20: Number of Products by Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD) 85
Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD) 86
Figure 22: Number of Products by Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD) 91
Figure 23: Number of Products by Stage and Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD) 91
Figure 24: Number of Products by Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD) 92
Figure 25: Number of Products by Stage and Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD) 93
Figure 26: Number of Products by Top 10 Targets, Idiopathic Pulmonary Fibrosis 94
Figure 27: Number of Products by Stage and Top 10 Targets, Idiopathic Pulmonary Fibrosis 94
Figure 28: Number of Products by Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis 97
Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis 98
Figure 30: Number of Products by Routes of Administration, Idiopathic Pulmonary Fibrosis 102
Figure 31: Number of Products by Stage and Routes of Administration, Idiopathic Pulmonary Fibrosis 102
Figure 32: Number of Products by Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis 103
Figure 33: Number of Products by Stage and Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis 104

  • Global Carbocisteine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 102
    According to our LPI (LP Information) latest study, the global Carbocisteine market size was valued at US$ 55 million in 2023. With growing demand in downstream market, the Carbocisteine is forecast to a readjusted size of US$ 76 million by 2030 with a CAGR of 4.9% during review period. The research report highlights the growth potential of the global Carbocisteine market. Carbocisteine are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Bovine Respiratory Disease Treatment Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 120
    Report Overview: Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for......
  • Global Ambroxol Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 91
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ambroxol market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Teva - Bayer - Novartis - Mylan - Bidachem - Hanmi - Hexal Pharma - Sris Pharmaceuticals - Hubei Ocean Biotechnology - DM Pharma......
  • Global Carbocisteine Professional Survey Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 3280 Onwards        Pages: 101
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Carbocisteine Market Research Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 2680 Onwards        Pages: 136
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Bovine Respiratory Disease Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 09-Nov-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Bovine Respiratory Disease Treatment market: According to our latest research, the global Bovine Respiratory Disease Treatment market looks promising in the next 5 years. As of 2022, the global Bovine Respiratory Disease Treatment market was estimated at USD 1748.69 million, and it's anticipated to reach USD 2423.79 million in 2028, with a CAGR of 5.59% during the forecast years. Bovine respiratory disease (BRD) is a multifactorial and complex diseas......
  • Respiratory Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 200
    Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding......
  • Global Drugs For Respiratory Syncytial Virus (Rsv) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Sep-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Drugs For Respiratory Syncytial Virus (Rsv) market: According to our latest research, the global Drugs For Respiratory Syncytial Virus (Rsv) market looks promising in the next 5 years. As of 2022, the global Drugs For Respiratory Syncytial Virus (Rsv) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and......
  • Global Ambroxol Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Sep-2023        Price: US 3380 Onwards        Pages: 127
    Market Overview of Global Ambroxol market: According to our latest research, the global Ambroxol market looks promising in the next 5 years. As of 2022, the global Ambroxol market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Ambroxol market, with a systematical descriptio......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs